Contact Information
Call us at: (614) 722-3550
Fax us at: (614) 722-3369
PediatricsHematology & Oncology700 Children’s DrColumbus, OH 43205 (map)
Learn more about Timothy P. Cripe
Biography
Timothy P. Cripe, MD, PhD, FAAP, is chief of the Division of Hematology and Oncology at Nationwide Children’s Hospital, a Gordon Teter Endowed Chair in Pediatric Cancer at Nationwide Children’s Hospital and a professor of pediatrics at The Ohio State University. Dr. Cripe received his undergraduate degree in Biochemistry from Princeton University and his M.D. and Ph.D. in Genetics from the University of Iowa. He completed his pediatric residency training at the University of Iowa Children’s Hospital and his subspecialty fellowship training in pediatric hematology/oncology from Dana-Farber Cancer Institute/Children’s Hospital, Boston and the University of Colorado/Children’s Hospital, Denver. He was on faculty at the University of Wisconsin-Madison and Cincinnati Children’s Hospital prior to coming to Nationwide Children’s.
Patient Care
Locations
Main Campus of Nationwide Children’s Hospital
Academic and Clinical Areas
Hematology/Oncology & BMT
Division Chief
Center for Childhood Cancer
Principal Investigator
Hematology, Oncology and BMT Fellowship
Faculty
Primary Department
Pediatrics
Primary Section
Hematology & Oncology
Awards, Honors & Organizations
Listed, Best Doctors in America
Research
Lab(s)
Center for Childhood Cancer
Dr. Cripe’s laboratory focuses on the development and testing of virus-based cancer immunotherapeutics. His team has a number of active projects to examine molecular and cellular features of various pediatric cancers that determine their response to virus injection, and are also pursuing strategies to modulate their response by altering the tumor immune microenvironment. Publications
Cripe TP. Cancer gene therapy bears fruit. Mol Ther. 2023 Jan 11;
Abdelbaki MS, DeWire Schottmiller MD, Cripe TP, Curry RC, Cruze CA, Her L, Demko S, Casey D, Setty B. An open-label multi-center phase 1 safety study of BXQ-350 in children and young adults with relapsed solid tumors, including recurrent malignant brain tumors. Heliyon. 2022 Dec; 8: e12450.
Kalathoor S, Rajendran S, Canella A, Raval R, Cripe TP, Mardis ER, Rajappa P. Myeloid cell heterogeneity in the tumor microenvironment and therapeutic implications for childhood central nervous system (CNS) tumors. J Neuroimmunol. 2022 Dec 5; 374: 578009.
Cripe TP, Hutzen B, Currier MA, Chen CY, Glaspell AM, Sullivan GC, Hurley JM, Deighen MR, Venkataramany AS, Mo X, Stanek JR, Miller AR, Wijeratne S, Magrini V, Mardis ER, Mendell JR, Chandler DS, Wang PY. Leveraging gene therapy to achieve long-term continuous or controllable expression of biotherapeutics. Sci Adv. 2022 Jul 15; 8: eabm1890.
Birnkrant DJ, Bello L, Butterfield RJ, Carter JC, Cripe LH, Cripe TP, McKim DA, Nandi D, Pegoraro E. Cardiorespiratory management of Duchenne muscular dystrophy: emerging therapies, neuromuscular genetics, and new clinical challenges. Lancet Respir Med. 2022 Apr; 10: 403-420.
Baliga S, Matsui J, Klamer B, Cetnar A, Ewing A, Cadieux C, Gupta A, Setty BA, Roberts RD, Olshefski RS, Cripe TP, Scharschmidt TJ, Aldrink J, Mardis E, Yeager ND, Palmer JD. Clinical outcomes and efficacy of stereotactic body radiation therapy in children, adolescents, and young adults with metastatic solid tumors. Br J Radiol. 2022 Feb 10; 20211088.
Gupta A, Cripe TP. Immunotherapies for Pediatric Solid Tumors: A Targeted Update. Paediatr Drugs. 2022 Jan; 24: 1-12.
Aggarwal P, Luo W, Pehlivan KC, Hoang H, Rajappa P, Cripe TP, Cassady KA, Lee DA, Cairo MS. Pediatric versus adult high grade glioma: Immunotherapeutic and genomic considerations. Front Immunol. 2022; 13: 1038096.
Wedekind MF, Miller KE, Chen CY, Wang PY, Hutzen BJ, Currier MA, Nartker B, Roberts RD, Boon L, Conner J, LaHaye S, Kelly BJ, Gordon D, White P, Mardis ER, Cripe TP. Endogenous retrovirus envelope as a tumor-associated immunotherapeutic target in murine osteosarcoma. iScience. 2021 Jul 23; 24: 102759.
McKim DA, Cripe TP, Cripe LH. The effect of emerging molecular and genetic therapies on cardiopulmonary disease in Duchenne muscular dystrophy. Pediatr Pulmonol. 2021 Apr; 56: 729-737.
Lipschitz N, Earl BR, Cripe TP, Samy RN. Oncolytic virotherapy: a potential therapeutic approach for cholesteatoma. Curr Opin Otolaryngol Head Neck Surg. 2020 Oct; 28: 281-285.
Wang Y, Stear JH, Swain A, Xu X, Bryce NS, Carnell M, Alieva IB, Dugina VB, Cripe TP, Stehn J, Hardeman EC, Gunning PW. Drug Targeting the Actin Cytoskeleton Potentiates the Cytotoxicity of Low Dose Vincristine by Abrogating Actin-Mediated Repair of Spindle Defects. Mol Cancer Res. 2020 Jul; 18: 1074-1087.
Auletta JJ, Adamson PC, Agin JE, Kearns P, Kennedy S, Kieran MW, Ludwinski DM, Knox LJ, McKay K, Rhiner P, Thiele CJ, Cripe TP. Pediatric cancer research: Surviving COVID-19. Pediatr Blood Cancer. 2020 Jun 18; e28435.
Charan M, Dravid P, Cam M, Audino A, Gross AC, Arnold MA, Roberts RD, Cripe TP, Pertsemlidis A, Houghton PJ, Cam H. GD2-directed CAR-T cells in combination with HGF-targeted neutralizing antibody (AMG102) prevent primary tumor growth and metastasis in Ewing sarcoma. Int J Cancer. 2020 Jun 1; 146: 3184-3195.
Wedekind MF, Cripe TP. Oncolytic Viruses and Their Potential as a Therapeutic Opportunity in Osteosarcoma. Adv Exp Med Biol. 2020; 1258: 77-89.
Yonkof JR, Gupta A, Rueda CM, Mangray S, Prince BT, Rangarajan HG, Alshahrani M, Varga E, Cripe TP, Abraham RS. A Novel Pathogenic Variant in CARMIL2 (RLTPR) Causing CARMIL2 Deficiency and EBV-Associated Smooth Muscle Tumors. Front Immunol. 2020; 11: 884.
Sette P, Amankulor N, Li A, Marzulli M, Leronni D, Zhang M, Goins WF, Kaur B, Bolyard C, Cripe TP, Yu J, Chiocca EA, Glorioso JC, Grandi P. GBM-Targeted oHSV Armed with Matrix Metalloproteinase 9 Enhances Anti-tumor Activity and Animal Survival. Mol Ther Oncolytics. 2019 Dec 20; 15: 214-222.
Hutzen B, Paudel SN, Naeimi Kararoudi M, Cassady KA, Lee DA, Cripe TP. Immunotherapies for pediatric cancer: current landscape and future perspectives. Cancer Metastasis Rev. 2019 Dec; 38: 573-594.
Hutzen B, Ghonime M, Lee J, Mardis ER, Wang R, Lee DA, Cairo MS, Roberts RD, Cripe TP, Cassady KA. Immunotherapeutic Challenges for Pediatric Cancers. Mol Ther Oncolytics. 2019 Dec 20; 15: 38-48.
Streby KA, Currier MA, Triplet M, Ott K, Dishman DJ, Vaughan MR, Ranalli MA, Setty B, Skeens MA, Whiteside S, Yeager ND, Haworth KB, Simpson K, Conner J, Cripe TP. First-in-Human Intravenous Seprehvir in Young Cancer Patients: A Phase 1 Clinical Trial. Mol Ther. 2019 Nov 6; 27: 1930-1938.
Samy RN, Earl BR, Lipschitz N, Schweinzger I, Currier M, Cripe T. Engineered oncolytic virus for the treatment of cholesteatoma: A pilot in vivo study. Laryngoscope Investig Otolaryngol. 2019 Oct; 4: 532-542.
Davis KA, Dodeja AK, Clark A, Hor K, Baker P, Cripe LH, Cripe TP. Use of Cardiac MRI to Assess Antitumor Efficacy of Everolimus in Sporadic Cardiac Rhabdomyoma. Pediatrics. 2019 Jun; 143:
Samy RN, Lipschitz N, Earl BR, Cripe TP. Evidence for Oncolytic Viral Eradication of Cholesteatoma In Vitro. Otolaryngol Head Neck Surg. 2019 May; 160: 891-893.
Orienti I, Cripe TP, Currier MA, Cavallari C, Teti G, Falconi M. A Cationic Nanomicellar Complex of the Quaternary Amphiphilic Amine RC16+ with Fenretinide as a New Multitasking System for Antitumor Therapy. Curr Drug Deliv. 2019; 16: 807-817.
Wedekind MF, Denton NL, Chen CY, Cripe TP. Pediatric Cancer Immunotherapy: Opportunities and Challenges. Paediatr Drugs. 2018 Oct; 20: 395-408.
Wedekind MF, Wagner LM, Cripe TP. Immunotherapy for osteosarcoma: Where do we go from here? Pediatr Blood Cancer. 2018 Sep; 65: e27227.
Sprague L, Braidwood L, Conner J, Cassady KA, Benencia F, Cripe TP. Please stand by: how oncolytic viruses impact bystander cells. Future Virol. 2018 Sep; 13: 671-680.
Cripe TP. After Hollywood Opened the Door, What Do We See in the Halls of Academic Medicine? Acad Med. 2018 Aug; 93: 1099-1100.
Fu X, Tao L, Wang PY, Cripe TP, Zhang X. Comparison of infectivity and spread between HSV-1 and HSV-2 based oncolytic viruses on tumor cells with different receptor expression profiles. Oncotarget. 2018 Apr 20; 9: 21348-21358.
Sprague L, Lee JM, Hutzen BJ, Wang PY, Chen CY, Conner J, Braidwood L, Cassady KA, Cripe TP. High Mobility Group Box 1 Influences HSV1716 Spread and Acts as an Adjuvant to Chemotherapy. Viruses. 2018 Mar 15; 10:
Chen CY, Hutzen B, Wedekind MF, Cripe TP. Oncolytic virus and PD-1/PD-L1 blockade combination therapy. Oncolytic Virother. 2018; 7: 65-77.
Franson T, Kinnett K, Cripe TP. Unique Burdens of Pediatric Clinical Trials in Duchenne Muscular Dystrophy, April 20-21, 2017, Bethesda, Maryland, USA. Ther Innov Regul Sci. 2018 Jan 1; 2168479018764650.
View More Publications
Education
Date of Appointment at Nationwide Children’s Hospital: 01/27/2012
Board Certifications
Pediatric Hematology Oncology
Fellowship
The Children’s Hospital - University of Colorado
Date Completed: 06/30/1995
Fellowship
Boston Children’s Hospital
Date Completed: 06/30/1993
Residency
University of Iowa Hospitals and Clinics
Date Completed: 07/01/1992
Medical School
University of Iowa
Date Completed: 05/06/1989
Contact Information
Pediatrics
Call us at: (614) 722-3550
Fax us at: (614) 722-3369
Hematology & Oncology700 Children's DrColumbus, OH 43205 (map)
Contact Information
Call us at: (614) 722-3550
Fax us at: (614) 722-3369
PediatricsHematology & Oncology700 Children’s DrColumbus, OH 43205 (map)
Learn more about Timothy P. Cripe
Biography
Timothy P. Cripe, MD, PhD, FAAP, is chief of the Division of Hematology and Oncology at Nationwide Children’s Hospital, a Gordon Teter Endowed Chair in Pediatric Cancer at Nationwide Children’s Hospital and a professor of pediatrics at The Ohio State University. Dr. Cripe received his undergraduate degree in Biochemistry from Princeton University and his M.D. and Ph.D. in Genetics from the University of Iowa. He completed his pediatric residency training at the University of Iowa Children’s Hospital and his subspecialty fellowship training in pediatric hematology/oncology from Dana-Farber Cancer Institute/Children’s Hospital, Boston and the University of Colorado/Children’s Hospital, Denver. He was on faculty at the University of Wisconsin-Madison and Cincinnati Children’s Hospital prior to coming to Nationwide Children’s.
Patient Care
Locations
Main Campus of Nationwide Children’s Hospital
Academic and Clinical Areas
Hematology/Oncology & BMT
Division Chief
Center for Childhood Cancer
Principal Investigator
Hematology, Oncology and BMT Fellowship
Faculty
Primary Department
Pediatrics
Primary Section
Hematology & Oncology
Awards, Honors & Organizations
Listed, Best Doctors in America
Research
Lab(s)
Center for Childhood Cancer
Dr. Cripe’s laboratory focuses on the development and testing of virus-based cancer immunotherapeutics. His team has a number of active projects to examine molecular and cellular features of various pediatric cancers that determine their response to virus injection, and are also pursuing strategies to modulate their response by altering the tumor immune microenvironment. Publications
Cripe TP. Cancer gene therapy bears fruit. Mol Ther. 2023 Jan 11;
Abdelbaki MS, DeWire Schottmiller MD, Cripe TP, Curry RC, Cruze CA, Her L, Demko S, Casey D, Setty B. An open-label multi-center phase 1 safety study of BXQ-350 in children and young adults with relapsed solid tumors, including recurrent malignant brain tumors. Heliyon. 2022 Dec; 8: e12450.
Kalathoor S, Rajendran S, Canella A, Raval R, Cripe TP, Mardis ER, Rajappa P. Myeloid cell heterogeneity in the tumor microenvironment and therapeutic implications for childhood central nervous system (CNS) tumors. J Neuroimmunol. 2022 Dec 5; 374: 578009.
Cripe TP, Hutzen B, Currier MA, Chen CY, Glaspell AM, Sullivan GC, Hurley JM, Deighen MR, Venkataramany AS, Mo X, Stanek JR, Miller AR, Wijeratne S, Magrini V, Mardis ER, Mendell JR, Chandler DS, Wang PY. Leveraging gene therapy to achieve long-term continuous or controllable expression of biotherapeutics. Sci Adv. 2022 Jul 15; 8: eabm1890.
Birnkrant DJ, Bello L, Butterfield RJ, Carter JC, Cripe LH, Cripe TP, McKim DA, Nandi D, Pegoraro E. Cardiorespiratory management of Duchenne muscular dystrophy: emerging therapies, neuromuscular genetics, and new clinical challenges. Lancet Respir Med. 2022 Apr; 10: 403-420.
Baliga S, Matsui J, Klamer B, Cetnar A, Ewing A, Cadieux C, Gupta A, Setty BA, Roberts RD, Olshefski RS, Cripe TP, Scharschmidt TJ, Aldrink J, Mardis E, Yeager ND, Palmer JD. Clinical outcomes and efficacy of stereotactic body radiation therapy in children, adolescents, and young adults with metastatic solid tumors. Br J Radiol. 2022 Feb 10; 20211088.
Gupta A, Cripe TP. Immunotherapies for Pediatric Solid Tumors: A Targeted Update. Paediatr Drugs. 2022 Jan; 24: 1-12.
Aggarwal P, Luo W, Pehlivan KC, Hoang H, Rajappa P, Cripe TP, Cassady KA, Lee DA, Cairo MS. Pediatric versus adult high grade glioma: Immunotherapeutic and genomic considerations. Front Immunol. 2022; 13: 1038096.
Wedekind MF, Miller KE, Chen CY, Wang PY, Hutzen BJ, Currier MA, Nartker B, Roberts RD, Boon L, Conner J, LaHaye S, Kelly BJ, Gordon D, White P, Mardis ER, Cripe TP. Endogenous retrovirus envelope as a tumor-associated immunotherapeutic target in murine osteosarcoma. iScience. 2021 Jul 23; 24: 102759.
McKim DA, Cripe TP, Cripe LH. The effect of emerging molecular and genetic therapies on cardiopulmonary disease in Duchenne muscular dystrophy. Pediatr Pulmonol. 2021 Apr; 56: 729-737.
Lipschitz N, Earl BR, Cripe TP, Samy RN. Oncolytic virotherapy: a potential therapeutic approach for cholesteatoma. Curr Opin Otolaryngol Head Neck Surg. 2020 Oct; 28: 281-285.
Wang Y, Stear JH, Swain A, Xu X, Bryce NS, Carnell M, Alieva IB, Dugina VB, Cripe TP, Stehn J, Hardeman EC, Gunning PW. Drug Targeting the Actin Cytoskeleton Potentiates the Cytotoxicity of Low Dose Vincristine by Abrogating Actin-Mediated Repair of Spindle Defects. Mol Cancer Res. 2020 Jul; 18: 1074-1087.
Auletta JJ, Adamson PC, Agin JE, Kearns P, Kennedy S, Kieran MW, Ludwinski DM, Knox LJ, McKay K, Rhiner P, Thiele CJ, Cripe TP. Pediatric cancer research: Surviving COVID-19. Pediatr Blood Cancer. 2020 Jun 18; e28435.
Charan M, Dravid P, Cam M, Audino A, Gross AC, Arnold MA, Roberts RD, Cripe TP, Pertsemlidis A, Houghton PJ, Cam H. GD2-directed CAR-T cells in combination with HGF-targeted neutralizing antibody (AMG102) prevent primary tumor growth and metastasis in Ewing sarcoma. Int J Cancer. 2020 Jun 1; 146: 3184-3195.
Wedekind MF, Cripe TP. Oncolytic Viruses and Their Potential as a Therapeutic Opportunity in Osteosarcoma. Adv Exp Med Biol. 2020; 1258: 77-89.
Yonkof JR, Gupta A, Rueda CM, Mangray S, Prince BT, Rangarajan HG, Alshahrani M, Varga E, Cripe TP, Abraham RS. A Novel Pathogenic Variant in CARMIL2 (RLTPR) Causing CARMIL2 Deficiency and EBV-Associated Smooth Muscle Tumors. Front Immunol. 2020; 11: 884.
Sette P, Amankulor N, Li A, Marzulli M, Leronni D, Zhang M, Goins WF, Kaur B, Bolyard C, Cripe TP, Yu J, Chiocca EA, Glorioso JC, Grandi P. GBM-Targeted oHSV Armed with Matrix Metalloproteinase 9 Enhances Anti-tumor Activity and Animal Survival. Mol Ther Oncolytics. 2019 Dec 20; 15: 214-222.
Hutzen B, Paudel SN, Naeimi Kararoudi M, Cassady KA, Lee DA, Cripe TP. Immunotherapies for pediatric cancer: current landscape and future perspectives. Cancer Metastasis Rev. 2019 Dec; 38: 573-594.
Hutzen B, Ghonime M, Lee J, Mardis ER, Wang R, Lee DA, Cairo MS, Roberts RD, Cripe TP, Cassady KA. Immunotherapeutic Challenges for Pediatric Cancers. Mol Ther Oncolytics. 2019 Dec 20; 15: 38-48.
Streby KA, Currier MA, Triplet M, Ott K, Dishman DJ, Vaughan MR, Ranalli MA, Setty B, Skeens MA, Whiteside S, Yeager ND, Haworth KB, Simpson K, Conner J, Cripe TP. First-in-Human Intravenous Seprehvir in Young Cancer Patients: A Phase 1 Clinical Trial. Mol Ther. 2019 Nov 6; 27: 1930-1938.
Samy RN, Earl BR, Lipschitz N, Schweinzger I, Currier M, Cripe T. Engineered oncolytic virus for the treatment of cholesteatoma: A pilot in vivo study. Laryngoscope Investig Otolaryngol. 2019 Oct; 4: 532-542.
Davis KA, Dodeja AK, Clark A, Hor K, Baker P, Cripe LH, Cripe TP. Use of Cardiac MRI to Assess Antitumor Efficacy of Everolimus in Sporadic Cardiac Rhabdomyoma. Pediatrics. 2019 Jun; 143:
Samy RN, Lipschitz N, Earl BR, Cripe TP. Evidence for Oncolytic Viral Eradication of Cholesteatoma In Vitro. Otolaryngol Head Neck Surg. 2019 May; 160: 891-893.
Orienti I, Cripe TP, Currier MA, Cavallari C, Teti G, Falconi M. A Cationic Nanomicellar Complex of the Quaternary Amphiphilic Amine RC16+ with Fenretinide as a New Multitasking System for Antitumor Therapy. Curr Drug Deliv. 2019; 16: 807-817.
Wedekind MF, Denton NL, Chen CY, Cripe TP. Pediatric Cancer Immunotherapy: Opportunities and Challenges. Paediatr Drugs. 2018 Oct; 20: 395-408.
Wedekind MF, Wagner LM, Cripe TP. Immunotherapy for osteosarcoma: Where do we go from here? Pediatr Blood Cancer. 2018 Sep; 65: e27227.
Sprague L, Braidwood L, Conner J, Cassady KA, Benencia F, Cripe TP. Please stand by: how oncolytic viruses impact bystander cells. Future Virol. 2018 Sep; 13: 671-680.
Cripe TP. After Hollywood Opened the Door, What Do We See in the Halls of Academic Medicine? Acad Med. 2018 Aug; 93: 1099-1100.
Fu X, Tao L, Wang PY, Cripe TP, Zhang X. Comparison of infectivity and spread between HSV-1 and HSV-2 based oncolytic viruses on tumor cells with different receptor expression profiles. Oncotarget. 2018 Apr 20; 9: 21348-21358.
Sprague L, Lee JM, Hutzen BJ, Wang PY, Chen CY, Conner J, Braidwood L, Cassady KA, Cripe TP. High Mobility Group Box 1 Influences HSV1716 Spread and Acts as an Adjuvant to Chemotherapy. Viruses. 2018 Mar 15; 10:
Chen CY, Hutzen B, Wedekind MF, Cripe TP. Oncolytic virus and PD-1/PD-L1 blockade combination therapy. Oncolytic Virother. 2018; 7: 65-77.
Franson T, Kinnett K, Cripe TP. Unique Burdens of Pediatric Clinical Trials in Duchenne Muscular Dystrophy, April 20-21, 2017, Bethesda, Maryland, USA. Ther Innov Regul Sci. 2018 Jan 1; 2168479018764650.
View More Publications
Education
Date of Appointment at Nationwide Children’s Hospital: 01/27/2012
Board Certifications
Pediatric Hematology Oncology
Fellowship
The Children’s Hospital - University of Colorado
Date Completed: 06/30/1995
Fellowship
Boston Children’s Hospital
Date Completed: 06/30/1993
Residency
University of Iowa Hospitals and Clinics
Date Completed: 07/01/1992
Medical School
University of Iowa
Date Completed: 05/06/1989
Contact Information
Pediatrics
Call us at: (614) 722-3550
Fax us at: (614) 722-3369
Hematology & Oncology700 Children's DrColumbus, OH 43205 (map)
Contact Information
Call us at: (614) 722-3550
Fax us at: (614) 722-3369
PediatricsHematology & Oncology700 Children’s DrColumbus, OH 43205 (map)
Learn more about Timothy P. Cripe
Contact Information
- Call us at:
- (614) 722-3550
- Fax us at:
- (614) 722-3369
- PediatricsHematology & Oncology700 Children’s DrColumbus, OH 43205 (map)
Learn more about Timothy P. Cripe
Biography
Timothy P. Cripe, MD, PhD, FAAP, is chief of the Division of Hematology and Oncology at Nationwide Children’s Hospital, a Gordon Teter Endowed Chair in Pediatric Cancer at Nationwide Children’s Hospital and a professor of pediatrics at The Ohio State University. Dr. Cripe received his undergraduate degree in Biochemistry from Princeton University and his M.D. and Ph.D. in Genetics from the University of Iowa. He completed his pediatric residency training at the University of Iowa Children’s Hospital and his subspecialty fellowship training in pediatric hematology/oncology from Dana-Farber Cancer Institute/Children’s Hospital, Boston and the University of Colorado/Children’s Hospital, Denver. He was on faculty at the University of Wisconsin-Madison and Cincinnati Children’s Hospital prior to coming to Nationwide Children’s.
Biography
Timothy P. Cripe, MD, PhD, FAAP, is chief of the Division of Hematology and Oncology at Nationwide Children’s Hospital, a Gordon Teter Endowed Chair in Pediatric Cancer at Nationwide Children’s Hospital and a professor of pediatrics at The Ohio State University. Dr. Cripe received his undergraduate degree in Biochemistry from Princeton University and his M.D. and Ph.D. in Genetics from the University of Iowa. He completed his pediatric residency training at the University of Iowa Children’s Hospital and his subspecialty fellowship training in pediatric hematology/oncology from Dana-Farber Cancer Institute/Children’s Hospital, Boston and the University of Colorado/Children’s Hospital, Denver. He was on faculty at the University of Wisconsin-Madison and Cincinnati Children’s Hospital prior to coming to Nationwide Children’s.
Biography
Timothy P. Cripe, MD, PhD, FAAP, is chief of the Division of Hematology and Oncology at Nationwide Children’s Hospital, a Gordon Teter Endowed Chair in Pediatric Cancer at Nationwide Children’s Hospital and a professor of pediatrics at The Ohio State University. Dr. Cripe received his undergraduate degree in Biochemistry from Princeton University and his M.D. and Ph.D. in Genetics from the University of Iowa. He completed his pediatric residency training at the University of Iowa Children’s Hospital and his subspecialty fellowship training in pediatric hematology/oncology from Dana-Farber Cancer Institute/Children’s Hospital, Boston and the University of Colorado/Children’s Hospital, Denver. He was on faculty at the University of Wisconsin-Madison and Cincinnati Children’s Hospital prior to coming to Nationwide Children’s.
Timothy P. Cripe, MD, PhD, FAAP, is chief of the Division of Hematology and Oncology at Nationwide Children’s Hospital, a Gordon Teter Endowed Chair in Pediatric Cancer at Nationwide Children’s Hospital and a professor of pediatrics at The Ohio State University. Dr. Cripe received his undergraduate degree in Biochemistry from Princeton University and his M.D. and Ph.D. in Genetics from the University of Iowa. He completed his pediatric residency training at the University of Iowa Children’s Hospital and his subspecialty fellowship training in pediatric hematology/oncology from Dana-Farber Cancer Institute/Children’s Hospital, Boston and the University of Colorado/Children’s Hospital, Denver. He was on faculty at the University of Wisconsin-Madison and Cincinnati Children’s Hospital prior to coming to Nationwide Children’s.
Timothy P. Cripe, MD, PhD, FAAP, is chief of the Division of Hematology and Oncology at Nationwide Children’s Hospital, a Gordon Teter Endowed Chair in Pediatric Cancer at Nationwide Children’s Hospital and a professor of pediatrics at The Ohio State University.
Dr. Cripe received his undergraduate degree in Biochemistry from Princeton University and his M.D. and Ph.D. in Genetics from the University of Iowa. He completed his pediatric residency training at the University of Iowa Children’s Hospital and his subspecialty fellowship training in pediatric hematology/oncology from Dana-Farber Cancer Institute/Children’s Hospital, Boston and the University of Colorado/Children’s Hospital, Denver. He was on faculty at the University of Wisconsin-Madison and Cincinnati Children’s Hospital prior to coming to Nationwide Children’s.
Patient Care
Locations
Main Campus of Nationwide Children’s Hospital
Patient Care
Locations
Main Campus of Nationwide Children’s Hospital
Patient Care
Locations
Main Campus of Nationwide Children’s Hospital
Locations
Main Campus of Nationwide Children’s Hospital
Locations
Main Campus of Nationwide Children’s Hospital
Locations
Main Campus of Nationwide Children’s Hospital
- Main Campus of Nationwide Children’s Hospital
Academic and Clinical Areas
Hematology/Oncology & BMT
Division Chief
Center for Childhood Cancer
Principal Investigator
Hematology, Oncology and BMT Fellowship
Faculty
Primary Department
Pediatrics
Primary Section
Hematology & Oncology
Academic and Clinical Areas
Hematology/Oncology & BMT
Division Chief
Center for Childhood Cancer
Principal Investigator
Hematology, Oncology and BMT Fellowship
Faculty
Primary Department
Pediatrics
Primary Section
Hematology & Oncology
Academic and Clinical Areas
Hematology/Oncology & BMT
Division Chief
Center for Childhood Cancer
Principal Investigator
Hematology, Oncology and BMT Fellowship
Faculty
Primary Department
Pediatrics
Primary Section
Hematology & Oncology
Hematology/Oncology & BMT
Division Chief
Center for Childhood Cancer
Principal Investigator
Hematology, Oncology and BMT Fellowship
Faculty
Primary Department
Pediatrics
Primary Section
Hematology & Oncology
- Hematology/Oncology & BMT
- Division Chief
- Center for Childhood Cancer
- Principal Investigator
- Hematology, Oncology and BMT Fellowship
- Faculty
- Primary Department
- Pediatrics
- Primary Section
- Hematology & Oncology
Awards, Honors & Organizations
Listed, Best Doctors in America
Awards, Honors & Organizations
Listed, Best Doctors in America
Awards, Honors & Organizations
Listed, Best Doctors in America
Listed, Best Doctors in America
- Listed, Best Doctors in America
Research
Lab(s)
Center for Childhood Cancer
Dr. Cripe’s laboratory focuses on the development and testing of virus-based cancer immunotherapeutics. His team has a number of active projects to examine molecular and cellular features of various pediatric cancers that determine their response to virus injection, and are also pursuing strategies to modulate their response by altering the tumor immune microenvironment. Publications
Cripe TP. Cancer gene therapy bears fruit. Mol Ther. 2023 Jan 11;
Abdelbaki MS, DeWire Schottmiller MD, Cripe TP, Curry RC, Cruze CA, Her L, Demko S, Casey D, Setty B. An open-label multi-center phase 1 safety study of BXQ-350 in children and young adults with relapsed solid tumors, including recurrent malignant brain tumors. Heliyon. 2022 Dec; 8: e12450.
Kalathoor S, Rajendran S, Canella A, Raval R, Cripe TP, Mardis ER, Rajappa P. Myeloid cell heterogeneity in the tumor microenvironment and therapeutic implications for childhood central nervous system (CNS) tumors. J Neuroimmunol. 2022 Dec 5; 374: 578009.
Cripe TP, Hutzen B, Currier MA, Chen CY, Glaspell AM, Sullivan GC, Hurley JM, Deighen MR, Venkataramany AS, Mo X, Stanek JR, Miller AR, Wijeratne S, Magrini V, Mardis ER, Mendell JR, Chandler DS, Wang PY. Leveraging gene therapy to achieve long-term continuous or controllable expression of biotherapeutics. Sci Adv. 2022 Jul 15; 8: eabm1890.
Birnkrant DJ, Bello L, Butterfield RJ, Carter JC, Cripe LH, Cripe TP, McKim DA, Nandi D, Pegoraro E. Cardiorespiratory management of Duchenne muscular dystrophy: emerging therapies, neuromuscular genetics, and new clinical challenges. Lancet Respir Med. 2022 Apr; 10: 403-420.
Baliga S, Matsui J, Klamer B, Cetnar A, Ewing A, Cadieux C, Gupta A, Setty BA, Roberts RD, Olshefski RS, Cripe TP, Scharschmidt TJ, Aldrink J, Mardis E, Yeager ND, Palmer JD. Clinical outcomes and efficacy of stereotactic body radiation therapy in children, adolescents, and young adults with metastatic solid tumors. Br J Radiol. 2022 Feb 10; 20211088.
Gupta A, Cripe TP. Immunotherapies for Pediatric Solid Tumors: A Targeted Update. Paediatr Drugs. 2022 Jan; 24: 1-12.
Aggarwal P, Luo W, Pehlivan KC, Hoang H, Rajappa P, Cripe TP, Cassady KA, Lee DA, Cairo MS. Pediatric versus adult high grade glioma: Immunotherapeutic and genomic considerations. Front Immunol. 2022; 13: 1038096.
Wedekind MF, Miller KE, Chen CY, Wang PY, Hutzen BJ, Currier MA, Nartker B, Roberts RD, Boon L, Conner J, LaHaye S, Kelly BJ, Gordon D, White P, Mardis ER, Cripe TP. Endogenous retrovirus envelope as a tumor-associated immunotherapeutic target in murine osteosarcoma. iScience. 2021 Jul 23; 24: 102759.
McKim DA, Cripe TP, Cripe LH. The effect of emerging molecular and genetic therapies on cardiopulmonary disease in Duchenne muscular dystrophy. Pediatr Pulmonol. 2021 Apr; 56: 729-737.
Lipschitz N, Earl BR, Cripe TP, Samy RN. Oncolytic virotherapy: a potential therapeutic approach for cholesteatoma. Curr Opin Otolaryngol Head Neck Surg. 2020 Oct; 28: 281-285.
Wang Y, Stear JH, Swain A, Xu X, Bryce NS, Carnell M, Alieva IB, Dugina VB, Cripe TP, Stehn J, Hardeman EC, Gunning PW. Drug Targeting the Actin Cytoskeleton Potentiates the Cytotoxicity of Low Dose Vincristine by Abrogating Actin-Mediated Repair of Spindle Defects. Mol Cancer Res. 2020 Jul; 18: 1074-1087.
Auletta JJ, Adamson PC, Agin JE, Kearns P, Kennedy S, Kieran MW, Ludwinski DM, Knox LJ, McKay K, Rhiner P, Thiele CJ, Cripe TP. Pediatric cancer research: Surviving COVID-19. Pediatr Blood Cancer. 2020 Jun 18; e28435.
Charan M, Dravid P, Cam M, Audino A, Gross AC, Arnold MA, Roberts RD, Cripe TP, Pertsemlidis A, Houghton PJ, Cam H. GD2-directed CAR-T cells in combination with HGF-targeted neutralizing antibody (AMG102) prevent primary tumor growth and metastasis in Ewing sarcoma. Int J Cancer. 2020 Jun 1; 146: 3184-3195.
Wedekind MF, Cripe TP. Oncolytic Viruses and Their Potential as a Therapeutic Opportunity in Osteosarcoma. Adv Exp Med Biol. 2020; 1258: 77-89.
Yonkof JR, Gupta A, Rueda CM, Mangray S, Prince BT, Rangarajan HG, Alshahrani M, Varga E, Cripe TP, Abraham RS. A Novel Pathogenic Variant in CARMIL2 (RLTPR) Causing CARMIL2 Deficiency and EBV-Associated Smooth Muscle Tumors. Front Immunol. 2020; 11: 884.
Sette P, Amankulor N, Li A, Marzulli M, Leronni D, Zhang M, Goins WF, Kaur B, Bolyard C, Cripe TP, Yu J, Chiocca EA, Glorioso JC, Grandi P. GBM-Targeted oHSV Armed with Matrix Metalloproteinase 9 Enhances Anti-tumor Activity and Animal Survival. Mol Ther Oncolytics. 2019 Dec 20; 15: 214-222.
Hutzen B, Paudel SN, Naeimi Kararoudi M, Cassady KA, Lee DA, Cripe TP. Immunotherapies for pediatric cancer: current landscape and future perspectives. Cancer Metastasis Rev. 2019 Dec; 38: 573-594.
Hutzen B, Ghonime M, Lee J, Mardis ER, Wang R, Lee DA, Cairo MS, Roberts RD, Cripe TP, Cassady KA. Immunotherapeutic Challenges for Pediatric Cancers. Mol Ther Oncolytics. 2019 Dec 20; 15: 38-48.
Streby KA, Currier MA, Triplet M, Ott K, Dishman DJ, Vaughan MR, Ranalli MA, Setty B, Skeens MA, Whiteside S, Yeager ND, Haworth KB, Simpson K, Conner J, Cripe TP. First-in-Human Intravenous Seprehvir in Young Cancer Patients: A Phase 1 Clinical Trial. Mol Ther. 2019 Nov 6; 27: 1930-1938.
Samy RN, Earl BR, Lipschitz N, Schweinzger I, Currier M, Cripe T. Engineered oncolytic virus for the treatment of cholesteatoma: A pilot in vivo study. Laryngoscope Investig Otolaryngol. 2019 Oct; 4: 532-542.
Davis KA, Dodeja AK, Clark A, Hor K, Baker P, Cripe LH, Cripe TP. Use of Cardiac MRI to Assess Antitumor Efficacy of Everolimus in Sporadic Cardiac Rhabdomyoma. Pediatrics. 2019 Jun; 143:
Samy RN, Lipschitz N, Earl BR, Cripe TP. Evidence for Oncolytic Viral Eradication of Cholesteatoma In Vitro. Otolaryngol Head Neck Surg. 2019 May; 160: 891-893.
Orienti I, Cripe TP, Currier MA, Cavallari C, Teti G, Falconi M. A Cationic Nanomicellar Complex of the Quaternary Amphiphilic Amine RC16+ with Fenretinide as a New Multitasking System for Antitumor Therapy. Curr Drug Deliv. 2019; 16: 807-817.
Wedekind MF, Denton NL, Chen CY, Cripe TP. Pediatric Cancer Immunotherapy: Opportunities and Challenges. Paediatr Drugs. 2018 Oct; 20: 395-408.
Wedekind MF, Wagner LM, Cripe TP. Immunotherapy for osteosarcoma: Where do we go from here? Pediatr Blood Cancer. 2018 Sep; 65: e27227.
Sprague L, Braidwood L, Conner J, Cassady KA, Benencia F, Cripe TP. Please stand by: how oncolytic viruses impact bystander cells. Future Virol. 2018 Sep; 13: 671-680.
Cripe TP. After Hollywood Opened the Door, What Do We See in the Halls of Academic Medicine? Acad Med. 2018 Aug; 93: 1099-1100.
Fu X, Tao L, Wang PY, Cripe TP, Zhang X. Comparison of infectivity and spread between HSV-1 and HSV-2 based oncolytic viruses on tumor cells with different receptor expression profiles. Oncotarget. 2018 Apr 20; 9: 21348-21358.
Sprague L, Lee JM, Hutzen BJ, Wang PY, Chen CY, Conner J, Braidwood L, Cassady KA, Cripe TP. High Mobility Group Box 1 Influences HSV1716 Spread and Acts as an Adjuvant to Chemotherapy. Viruses. 2018 Mar 15; 10:
Chen CY, Hutzen B, Wedekind MF, Cripe TP. Oncolytic virus and PD-1/PD-L1 blockade combination therapy. Oncolytic Virother. 2018; 7: 65-77.
Franson T, Kinnett K, Cripe TP. Unique Burdens of Pediatric Clinical Trials in Duchenne Muscular Dystrophy, April 20-21, 2017, Bethesda, Maryland, USA. Ther Innov Regul Sci. 2018 Jan 1; 2168479018764650.
View More Publications
Research
Lab(s)
Center for Childhood Cancer
Dr. Cripe’s laboratory focuses on the development and testing of virus-based cancer immunotherapeutics. His team has a number of active projects to examine molecular and cellular features of various pediatric cancers that determine their response to virus injection, and are also pursuing strategies to modulate their response by altering the tumor immune microenvironment. Publications
Cripe TP. Cancer gene therapy bears fruit. Mol Ther. 2023 Jan 11;
Abdelbaki MS, DeWire Schottmiller MD, Cripe TP, Curry RC, Cruze CA, Her L, Demko S, Casey D, Setty B. An open-label multi-center phase 1 safety study of BXQ-350 in children and young adults with relapsed solid tumors, including recurrent malignant brain tumors. Heliyon. 2022 Dec; 8: e12450.
Kalathoor S, Rajendran S, Canella A, Raval R, Cripe TP, Mardis ER, Rajappa P. Myeloid cell heterogeneity in the tumor microenvironment and therapeutic implications for childhood central nervous system (CNS) tumors. J Neuroimmunol. 2022 Dec 5; 374: 578009.
Cripe TP, Hutzen B, Currier MA, Chen CY, Glaspell AM, Sullivan GC, Hurley JM, Deighen MR, Venkataramany AS, Mo X, Stanek JR, Miller AR, Wijeratne S, Magrini V, Mardis ER, Mendell JR, Chandler DS, Wang PY. Leveraging gene therapy to achieve long-term continuous or controllable expression of biotherapeutics. Sci Adv. 2022 Jul 15; 8: eabm1890.
Birnkrant DJ, Bello L, Butterfield RJ, Carter JC, Cripe LH, Cripe TP, McKim DA, Nandi D, Pegoraro E. Cardiorespiratory management of Duchenne muscular dystrophy: emerging therapies, neuromuscular genetics, and new clinical challenges. Lancet Respir Med. 2022 Apr; 10: 403-420.
Baliga S, Matsui J, Klamer B, Cetnar A, Ewing A, Cadieux C, Gupta A, Setty BA, Roberts RD, Olshefski RS, Cripe TP, Scharschmidt TJ, Aldrink J, Mardis E, Yeager ND, Palmer JD. Clinical outcomes and efficacy of stereotactic body radiation therapy in children, adolescents, and young adults with metastatic solid tumors. Br J Radiol. 2022 Feb 10; 20211088.
Gupta A, Cripe TP. Immunotherapies for Pediatric Solid Tumors: A Targeted Update. Paediatr Drugs. 2022 Jan; 24: 1-12.
Aggarwal P, Luo W, Pehlivan KC, Hoang H, Rajappa P, Cripe TP, Cassady KA, Lee DA, Cairo MS. Pediatric versus adult high grade glioma: Immunotherapeutic and genomic considerations. Front Immunol. 2022; 13: 1038096.
Wedekind MF, Miller KE, Chen CY, Wang PY, Hutzen BJ, Currier MA, Nartker B, Roberts RD, Boon L, Conner J, LaHaye S, Kelly BJ, Gordon D, White P, Mardis ER, Cripe TP. Endogenous retrovirus envelope as a tumor-associated immunotherapeutic target in murine osteosarcoma. iScience. 2021 Jul 23; 24: 102759.
McKim DA, Cripe TP, Cripe LH. The effect of emerging molecular and genetic therapies on cardiopulmonary disease in Duchenne muscular dystrophy. Pediatr Pulmonol. 2021 Apr; 56: 729-737.
Lipschitz N, Earl BR, Cripe TP, Samy RN. Oncolytic virotherapy: a potential therapeutic approach for cholesteatoma. Curr Opin Otolaryngol Head Neck Surg. 2020 Oct; 28: 281-285.
Wang Y, Stear JH, Swain A, Xu X, Bryce NS, Carnell M, Alieva IB, Dugina VB, Cripe TP, Stehn J, Hardeman EC, Gunning PW. Drug Targeting the Actin Cytoskeleton Potentiates the Cytotoxicity of Low Dose Vincristine by Abrogating Actin-Mediated Repair of Spindle Defects. Mol Cancer Res. 2020 Jul; 18: 1074-1087.
Auletta JJ, Adamson PC, Agin JE, Kearns P, Kennedy S, Kieran MW, Ludwinski DM, Knox LJ, McKay K, Rhiner P, Thiele CJ, Cripe TP. Pediatric cancer research: Surviving COVID-19. Pediatr Blood Cancer. 2020 Jun 18; e28435.
Charan M, Dravid P, Cam M, Audino A, Gross AC, Arnold MA, Roberts RD, Cripe TP, Pertsemlidis A, Houghton PJ, Cam H. GD2-directed CAR-T cells in combination with HGF-targeted neutralizing antibody (AMG102) prevent primary tumor growth and metastasis in Ewing sarcoma. Int J Cancer. 2020 Jun 1; 146: 3184-3195.
Wedekind MF, Cripe TP. Oncolytic Viruses and Their Potential as a Therapeutic Opportunity in Osteosarcoma. Adv Exp Med Biol. 2020; 1258: 77-89.
Yonkof JR, Gupta A, Rueda CM, Mangray S, Prince BT, Rangarajan HG, Alshahrani M, Varga E, Cripe TP, Abraham RS. A Novel Pathogenic Variant in CARMIL2 (RLTPR) Causing CARMIL2 Deficiency and EBV-Associated Smooth Muscle Tumors. Front Immunol. 2020; 11: 884.
Sette P, Amankulor N, Li A, Marzulli M, Leronni D, Zhang M, Goins WF, Kaur B, Bolyard C, Cripe TP, Yu J, Chiocca EA, Glorioso JC, Grandi P. GBM-Targeted oHSV Armed with Matrix Metalloproteinase 9 Enhances Anti-tumor Activity and Animal Survival. Mol Ther Oncolytics. 2019 Dec 20; 15: 214-222.
Hutzen B, Paudel SN, Naeimi Kararoudi M, Cassady KA, Lee DA, Cripe TP. Immunotherapies for pediatric cancer: current landscape and future perspectives. Cancer Metastasis Rev. 2019 Dec; 38: 573-594.
Hutzen B, Ghonime M, Lee J, Mardis ER, Wang R, Lee DA, Cairo MS, Roberts RD, Cripe TP, Cassady KA. Immunotherapeutic Challenges for Pediatric Cancers. Mol Ther Oncolytics. 2019 Dec 20; 15: 38-48.
Streby KA, Currier MA, Triplet M, Ott K, Dishman DJ, Vaughan MR, Ranalli MA, Setty B, Skeens MA, Whiteside S, Yeager ND, Haworth KB, Simpson K, Conner J, Cripe TP. First-in-Human Intravenous Seprehvir in Young Cancer Patients: A Phase 1 Clinical Trial. Mol Ther. 2019 Nov 6; 27: 1930-1938.
Samy RN, Earl BR, Lipschitz N, Schweinzger I, Currier M, Cripe T. Engineered oncolytic virus for the treatment of cholesteatoma: A pilot in vivo study. Laryngoscope Investig Otolaryngol. 2019 Oct; 4: 532-542.
Davis KA, Dodeja AK, Clark A, Hor K, Baker P, Cripe LH, Cripe TP. Use of Cardiac MRI to Assess Antitumor Efficacy of Everolimus in Sporadic Cardiac Rhabdomyoma. Pediatrics. 2019 Jun; 143:
Samy RN, Lipschitz N, Earl BR, Cripe TP. Evidence for Oncolytic Viral Eradication of Cholesteatoma In Vitro. Otolaryngol Head Neck Surg. 2019 May; 160: 891-893.
Orienti I, Cripe TP, Currier MA, Cavallari C, Teti G, Falconi M. A Cationic Nanomicellar Complex of the Quaternary Amphiphilic Amine RC16+ with Fenretinide as a New Multitasking System for Antitumor Therapy. Curr Drug Deliv. 2019; 16: 807-817.
Wedekind MF, Denton NL, Chen CY, Cripe TP. Pediatric Cancer Immunotherapy: Opportunities and Challenges. Paediatr Drugs. 2018 Oct; 20: 395-408.
Wedekind MF, Wagner LM, Cripe TP. Immunotherapy for osteosarcoma: Where do we go from here? Pediatr Blood Cancer. 2018 Sep; 65: e27227.
Sprague L, Braidwood L, Conner J, Cassady KA, Benencia F, Cripe TP. Please stand by: how oncolytic viruses impact bystander cells. Future Virol. 2018 Sep; 13: 671-680.
Cripe TP. After Hollywood Opened the Door, What Do We See in the Halls of Academic Medicine? Acad Med. 2018 Aug; 93: 1099-1100.
Fu X, Tao L, Wang PY, Cripe TP, Zhang X. Comparison of infectivity and spread between HSV-1 and HSV-2 based oncolytic viruses on tumor cells with different receptor expression profiles. Oncotarget. 2018 Apr 20; 9: 21348-21358.
Sprague L, Lee JM, Hutzen BJ, Wang PY, Chen CY, Conner J, Braidwood L, Cassady KA, Cripe TP. High Mobility Group Box 1 Influences HSV1716 Spread and Acts as an Adjuvant to Chemotherapy. Viruses. 2018 Mar 15; 10:
Chen CY, Hutzen B, Wedekind MF, Cripe TP. Oncolytic virus and PD-1/PD-L1 blockade combination therapy. Oncolytic Virother. 2018; 7: 65-77.
Franson T, Kinnett K, Cripe TP. Unique Burdens of Pediatric Clinical Trials in Duchenne Muscular Dystrophy, April 20-21, 2017, Bethesda, Maryland, USA. Ther Innov Regul Sci. 2018 Jan 1; 2168479018764650.
View More Publications
Research
Lab(s)
Center for Childhood Cancer
Dr. Cripe’s laboratory focuses on the development and testing of virus-based cancer immunotherapeutics. His team has a number of active projects to examine molecular and cellular features of various pediatric cancers that determine their response to virus injection, and are also pursuing strategies to modulate their response by altering the tumor immune microenvironment. Publications
Cripe TP. Cancer gene therapy bears fruit. Mol Ther. 2023 Jan 11;
Abdelbaki MS, DeWire Schottmiller MD, Cripe TP, Curry RC, Cruze CA, Her L, Demko S, Casey D, Setty B. An open-label multi-center phase 1 safety study of BXQ-350 in children and young adults with relapsed solid tumors, including recurrent malignant brain tumors. Heliyon. 2022 Dec; 8: e12450.
Kalathoor S, Rajendran S, Canella A, Raval R, Cripe TP, Mardis ER, Rajappa P. Myeloid cell heterogeneity in the tumor microenvironment and therapeutic implications for childhood central nervous system (CNS) tumors. J Neuroimmunol. 2022 Dec 5; 374: 578009.
Cripe TP, Hutzen B, Currier MA, Chen CY, Glaspell AM, Sullivan GC, Hurley JM, Deighen MR, Venkataramany AS, Mo X, Stanek JR, Miller AR, Wijeratne S, Magrini V, Mardis ER, Mendell JR, Chandler DS, Wang PY. Leveraging gene therapy to achieve long-term continuous or controllable expression of biotherapeutics. Sci Adv. 2022 Jul 15; 8: eabm1890.
Birnkrant DJ, Bello L, Butterfield RJ, Carter JC, Cripe LH, Cripe TP, McKim DA, Nandi D, Pegoraro E. Cardiorespiratory management of Duchenne muscular dystrophy: emerging therapies, neuromuscular genetics, and new clinical challenges. Lancet Respir Med. 2022 Apr; 10: 403-420.
Baliga S, Matsui J, Klamer B, Cetnar A, Ewing A, Cadieux C, Gupta A, Setty BA, Roberts RD, Olshefski RS, Cripe TP, Scharschmidt TJ, Aldrink J, Mardis E, Yeager ND, Palmer JD. Clinical outcomes and efficacy of stereotactic body radiation therapy in children, adolescents, and young adults with metastatic solid tumors. Br J Radiol. 2022 Feb 10; 20211088.
Gupta A, Cripe TP. Immunotherapies for Pediatric Solid Tumors: A Targeted Update. Paediatr Drugs. 2022 Jan; 24: 1-12.
Aggarwal P, Luo W, Pehlivan KC, Hoang H, Rajappa P, Cripe TP, Cassady KA, Lee DA, Cairo MS. Pediatric versus adult high grade glioma: Immunotherapeutic and genomic considerations. Front Immunol. 2022; 13: 1038096.
Wedekind MF, Miller KE, Chen CY, Wang PY, Hutzen BJ, Currier MA, Nartker B, Roberts RD, Boon L, Conner J, LaHaye S, Kelly BJ, Gordon D, White P, Mardis ER, Cripe TP. Endogenous retrovirus envelope as a tumor-associated immunotherapeutic target in murine osteosarcoma. iScience. 2021 Jul 23; 24: 102759.
McKim DA, Cripe TP, Cripe LH. The effect of emerging molecular and genetic therapies on cardiopulmonary disease in Duchenne muscular dystrophy. Pediatr Pulmonol. 2021 Apr; 56: 729-737.
Lipschitz N, Earl BR, Cripe TP, Samy RN. Oncolytic virotherapy: a potential therapeutic approach for cholesteatoma. Curr Opin Otolaryngol Head Neck Surg. 2020 Oct; 28: 281-285.
Wang Y, Stear JH, Swain A, Xu X, Bryce NS, Carnell M, Alieva IB, Dugina VB, Cripe TP, Stehn J, Hardeman EC, Gunning PW. Drug Targeting the Actin Cytoskeleton Potentiates the Cytotoxicity of Low Dose Vincristine by Abrogating Actin-Mediated Repair of Spindle Defects. Mol Cancer Res. 2020 Jul; 18: 1074-1087.
Auletta JJ, Adamson PC, Agin JE, Kearns P, Kennedy S, Kieran MW, Ludwinski DM, Knox LJ, McKay K, Rhiner P, Thiele CJ, Cripe TP. Pediatric cancer research: Surviving COVID-19. Pediatr Blood Cancer. 2020 Jun 18; e28435.
Charan M, Dravid P, Cam M, Audino A, Gross AC, Arnold MA, Roberts RD, Cripe TP, Pertsemlidis A, Houghton PJ, Cam H. GD2-directed CAR-T cells in combination with HGF-targeted neutralizing antibody (AMG102) prevent primary tumor growth and metastasis in Ewing sarcoma. Int J Cancer. 2020 Jun 1; 146: 3184-3195.
Wedekind MF, Cripe TP. Oncolytic Viruses and Their Potential as a Therapeutic Opportunity in Osteosarcoma. Adv Exp Med Biol. 2020; 1258: 77-89.
Yonkof JR, Gupta A, Rueda CM, Mangray S, Prince BT, Rangarajan HG, Alshahrani M, Varga E, Cripe TP, Abraham RS. A Novel Pathogenic Variant in CARMIL2 (RLTPR) Causing CARMIL2 Deficiency and EBV-Associated Smooth Muscle Tumors. Front Immunol. 2020; 11: 884.
Sette P, Amankulor N, Li A, Marzulli M, Leronni D, Zhang M, Goins WF, Kaur B, Bolyard C, Cripe TP, Yu J, Chiocca EA, Glorioso JC, Grandi P. GBM-Targeted oHSV Armed with Matrix Metalloproteinase 9 Enhances Anti-tumor Activity and Animal Survival. Mol Ther Oncolytics. 2019 Dec 20; 15: 214-222.
Hutzen B, Paudel SN, Naeimi Kararoudi M, Cassady KA, Lee DA, Cripe TP. Immunotherapies for pediatric cancer: current landscape and future perspectives. Cancer Metastasis Rev. 2019 Dec; 38: 573-594.
Hutzen B, Ghonime M, Lee J, Mardis ER, Wang R, Lee DA, Cairo MS, Roberts RD, Cripe TP, Cassady KA. Immunotherapeutic Challenges for Pediatric Cancers. Mol Ther Oncolytics. 2019 Dec 20; 15: 38-48.
Streby KA, Currier MA, Triplet M, Ott K, Dishman DJ, Vaughan MR, Ranalli MA, Setty B, Skeens MA, Whiteside S, Yeager ND, Haworth KB, Simpson K, Conner J, Cripe TP. First-in-Human Intravenous Seprehvir in Young Cancer Patients: A Phase 1 Clinical Trial. Mol Ther. 2019 Nov 6; 27: 1930-1938.
Samy RN, Earl BR, Lipschitz N, Schweinzger I, Currier M, Cripe T. Engineered oncolytic virus for the treatment of cholesteatoma: A pilot in vivo study. Laryngoscope Investig Otolaryngol. 2019 Oct; 4: 532-542.
Davis KA, Dodeja AK, Clark A, Hor K, Baker P, Cripe LH, Cripe TP. Use of Cardiac MRI to Assess Antitumor Efficacy of Everolimus in Sporadic Cardiac Rhabdomyoma. Pediatrics. 2019 Jun; 143:
Samy RN, Lipschitz N, Earl BR, Cripe TP. Evidence for Oncolytic Viral Eradication of Cholesteatoma In Vitro. Otolaryngol Head Neck Surg. 2019 May; 160: 891-893.
Orienti I, Cripe TP, Currier MA, Cavallari C, Teti G, Falconi M. A Cationic Nanomicellar Complex of the Quaternary Amphiphilic Amine RC16+ with Fenretinide as a New Multitasking System for Antitumor Therapy. Curr Drug Deliv. 2019; 16: 807-817.
Wedekind MF, Denton NL, Chen CY, Cripe TP. Pediatric Cancer Immunotherapy: Opportunities and Challenges. Paediatr Drugs. 2018 Oct; 20: 395-408.
Wedekind MF, Wagner LM, Cripe TP. Immunotherapy for osteosarcoma: Where do we go from here? Pediatr Blood Cancer. 2018 Sep; 65: e27227.
Sprague L, Braidwood L, Conner J, Cassady KA, Benencia F, Cripe TP. Please stand by: how oncolytic viruses impact bystander cells. Future Virol. 2018 Sep; 13: 671-680.
Cripe TP. After Hollywood Opened the Door, What Do We See in the Halls of Academic Medicine? Acad Med. 2018 Aug; 93: 1099-1100.
Fu X, Tao L, Wang PY, Cripe TP, Zhang X. Comparison of infectivity and spread between HSV-1 and HSV-2 based oncolytic viruses on tumor cells with different receptor expression profiles. Oncotarget. 2018 Apr 20; 9: 21348-21358.
Sprague L, Lee JM, Hutzen BJ, Wang PY, Chen CY, Conner J, Braidwood L, Cassady KA, Cripe TP. High Mobility Group Box 1 Influences HSV1716 Spread and Acts as an Adjuvant to Chemotherapy. Viruses. 2018 Mar 15; 10:
Chen CY, Hutzen B, Wedekind MF, Cripe TP. Oncolytic virus and PD-1/PD-L1 blockade combination therapy. Oncolytic Virother. 2018; 7: 65-77.
Franson T, Kinnett K, Cripe TP. Unique Burdens of Pediatric Clinical Trials in Duchenne Muscular Dystrophy, April 20-21, 2017, Bethesda, Maryland, USA. Ther Innov Regul Sci. 2018 Jan 1; 2168479018764650.
View More Publications
Lab(s)
Center for Childhood Cancer
Dr. Cripe’s laboratory focuses on the development and testing of virus-based cancer immunotherapeutics. His team has a number of active projects to examine molecular and cellular features of various pediatric cancers that determine their response to virus injection, and are also pursuing strategies to modulate their response by altering the tumor immune microenvironment. Publications
Cripe TP. Cancer gene therapy bears fruit. Mol Ther. 2023 Jan 11;
Abdelbaki MS, DeWire Schottmiller MD, Cripe TP, Curry RC, Cruze CA, Her L, Demko S, Casey D, Setty B. An open-label multi-center phase 1 safety study of BXQ-350 in children and young adults with relapsed solid tumors, including recurrent malignant brain tumors. Heliyon. 2022 Dec; 8: e12450.
Kalathoor S, Rajendran S, Canella A, Raval R, Cripe TP, Mardis ER, Rajappa P. Myeloid cell heterogeneity in the tumor microenvironment and therapeutic implications for childhood central nervous system (CNS) tumors. J Neuroimmunol. 2022 Dec 5; 374: 578009.
Cripe TP, Hutzen B, Currier MA, Chen CY, Glaspell AM, Sullivan GC, Hurley JM, Deighen MR, Venkataramany AS, Mo X, Stanek JR, Miller AR, Wijeratne S, Magrini V, Mardis ER, Mendell JR, Chandler DS, Wang PY. Leveraging gene therapy to achieve long-term continuous or controllable expression of biotherapeutics. Sci Adv. 2022 Jul 15; 8: eabm1890.
Birnkrant DJ, Bello L, Butterfield RJ, Carter JC, Cripe LH, Cripe TP, McKim DA, Nandi D, Pegoraro E. Cardiorespiratory management of Duchenne muscular dystrophy: emerging therapies, neuromuscular genetics, and new clinical challenges. Lancet Respir Med. 2022 Apr; 10: 403-420.
Baliga S, Matsui J, Klamer B, Cetnar A, Ewing A, Cadieux C, Gupta A, Setty BA, Roberts RD, Olshefski RS, Cripe TP, Scharschmidt TJ, Aldrink J, Mardis E, Yeager ND, Palmer JD. Clinical outcomes and efficacy of stereotactic body radiation therapy in children, adolescents, and young adults with metastatic solid tumors. Br J Radiol. 2022 Feb 10; 20211088.
Gupta A, Cripe TP. Immunotherapies for Pediatric Solid Tumors: A Targeted Update. Paediatr Drugs. 2022 Jan; 24: 1-12.
Aggarwal P, Luo W, Pehlivan KC, Hoang H, Rajappa P, Cripe TP, Cassady KA, Lee DA, Cairo MS. Pediatric versus adult high grade glioma: Immunotherapeutic and genomic considerations. Front Immunol. 2022; 13: 1038096.
Wedekind MF, Miller KE, Chen CY, Wang PY, Hutzen BJ, Currier MA, Nartker B, Roberts RD, Boon L, Conner J, LaHaye S, Kelly BJ, Gordon D, White P, Mardis ER, Cripe TP. Endogenous retrovirus envelope as a tumor-associated immunotherapeutic target in murine osteosarcoma. iScience. 2021 Jul 23; 24: 102759.
McKim DA, Cripe TP, Cripe LH. The effect of emerging molecular and genetic therapies on cardiopulmonary disease in Duchenne muscular dystrophy. Pediatr Pulmonol. 2021 Apr; 56: 729-737.
Lipschitz N, Earl BR, Cripe TP, Samy RN. Oncolytic virotherapy: a potential therapeutic approach for cholesteatoma. Curr Opin Otolaryngol Head Neck Surg. 2020 Oct; 28: 281-285.
Wang Y, Stear JH, Swain A, Xu X, Bryce NS, Carnell M, Alieva IB, Dugina VB, Cripe TP, Stehn J, Hardeman EC, Gunning PW. Drug Targeting the Actin Cytoskeleton Potentiates the Cytotoxicity of Low Dose Vincristine by Abrogating Actin-Mediated Repair of Spindle Defects. Mol Cancer Res. 2020 Jul; 18: 1074-1087.
Auletta JJ, Adamson PC, Agin JE, Kearns P, Kennedy S, Kieran MW, Ludwinski DM, Knox LJ, McKay K, Rhiner P, Thiele CJ, Cripe TP. Pediatric cancer research: Surviving COVID-19. Pediatr Blood Cancer. 2020 Jun 18; e28435.
Charan M, Dravid P, Cam M, Audino A, Gross AC, Arnold MA, Roberts RD, Cripe TP, Pertsemlidis A, Houghton PJ, Cam H. GD2-directed CAR-T cells in combination with HGF-targeted neutralizing antibody (AMG102) prevent primary tumor growth and metastasis in Ewing sarcoma. Int J Cancer. 2020 Jun 1; 146: 3184-3195.
Wedekind MF, Cripe TP. Oncolytic Viruses and Their Potential as a Therapeutic Opportunity in Osteosarcoma. Adv Exp Med Biol. 2020; 1258: 77-89.
Yonkof JR, Gupta A, Rueda CM, Mangray S, Prince BT, Rangarajan HG, Alshahrani M, Varga E, Cripe TP, Abraham RS. A Novel Pathogenic Variant in CARMIL2 (RLTPR) Causing CARMIL2 Deficiency and EBV-Associated Smooth Muscle Tumors. Front Immunol. 2020; 11: 884.
Sette P, Amankulor N, Li A, Marzulli M, Leronni D, Zhang M, Goins WF, Kaur B, Bolyard C, Cripe TP, Yu J, Chiocca EA, Glorioso JC, Grandi P. GBM-Targeted oHSV Armed with Matrix Metalloproteinase 9 Enhances Anti-tumor Activity and Animal Survival. Mol Ther Oncolytics. 2019 Dec 20; 15: 214-222.
Hutzen B, Paudel SN, Naeimi Kararoudi M, Cassady KA, Lee DA, Cripe TP. Immunotherapies for pediatric cancer: current landscape and future perspectives. Cancer Metastasis Rev. 2019 Dec; 38: 573-594.
Hutzen B, Ghonime M, Lee J, Mardis ER, Wang R, Lee DA, Cairo MS, Roberts RD, Cripe TP, Cassady KA. Immunotherapeutic Challenges for Pediatric Cancers. Mol Ther Oncolytics. 2019 Dec 20; 15: 38-48.
Streby KA, Currier MA, Triplet M, Ott K, Dishman DJ, Vaughan MR, Ranalli MA, Setty B, Skeens MA, Whiteside S, Yeager ND, Haworth KB, Simpson K, Conner J, Cripe TP. First-in-Human Intravenous Seprehvir in Young Cancer Patients: A Phase 1 Clinical Trial. Mol Ther. 2019 Nov 6; 27: 1930-1938.
Samy RN, Earl BR, Lipschitz N, Schweinzger I, Currier M, Cripe T. Engineered oncolytic virus for the treatment of cholesteatoma: A pilot in vivo study. Laryngoscope Investig Otolaryngol. 2019 Oct; 4: 532-542.
Davis KA, Dodeja AK, Clark A, Hor K, Baker P, Cripe LH, Cripe TP. Use of Cardiac MRI to Assess Antitumor Efficacy of Everolimus in Sporadic Cardiac Rhabdomyoma. Pediatrics. 2019 Jun; 143:
Samy RN, Lipschitz N, Earl BR, Cripe TP. Evidence for Oncolytic Viral Eradication of Cholesteatoma In Vitro. Otolaryngol Head Neck Surg. 2019 May; 160: 891-893.
Orienti I, Cripe TP, Currier MA, Cavallari C, Teti G, Falconi M. A Cationic Nanomicellar Complex of the Quaternary Amphiphilic Amine RC16+ with Fenretinide as a New Multitasking System for Antitumor Therapy. Curr Drug Deliv. 2019; 16: 807-817.
Wedekind MF, Denton NL, Chen CY, Cripe TP. Pediatric Cancer Immunotherapy: Opportunities and Challenges. Paediatr Drugs. 2018 Oct; 20: 395-408.
Wedekind MF, Wagner LM, Cripe TP. Immunotherapy for osteosarcoma: Where do we go from here? Pediatr Blood Cancer. 2018 Sep; 65: e27227.
Sprague L, Braidwood L, Conner J, Cassady KA, Benencia F, Cripe TP. Please stand by: how oncolytic viruses impact bystander cells. Future Virol. 2018 Sep; 13: 671-680.
Cripe TP. After Hollywood Opened the Door, What Do We See in the Halls of Academic Medicine? Acad Med. 2018 Aug; 93: 1099-1100.
Fu X, Tao L, Wang PY, Cripe TP, Zhang X. Comparison of infectivity and spread between HSV-1 and HSV-2 based oncolytic viruses on tumor cells with different receptor expression profiles. Oncotarget. 2018 Apr 20; 9: 21348-21358.
Sprague L, Lee JM, Hutzen BJ, Wang PY, Chen CY, Conner J, Braidwood L, Cassady KA, Cripe TP. High Mobility Group Box 1 Influences HSV1716 Spread and Acts as an Adjuvant to Chemotherapy. Viruses. 2018 Mar 15; 10:
Chen CY, Hutzen B, Wedekind MF, Cripe TP. Oncolytic virus and PD-1/PD-L1 blockade combination therapy. Oncolytic Virother. 2018; 7: 65-77.
Franson T, Kinnett K, Cripe TP. Unique Burdens of Pediatric Clinical Trials in Duchenne Muscular Dystrophy, April 20-21, 2017, Bethesda, Maryland, USA. Ther Innov Regul Sci. 2018 Jan 1; 2168479018764650.
View More Publications
Lab(s)
Center for Childhood Cancer
Dr. Cripe’s laboratory focuses on the development and testing of virus-based cancer immunotherapeutics. His team has a number of active projects to examine molecular and cellular features of various pediatric cancers that determine their response to virus injection, and are also pursuing strategies to modulate their response by altering the tumor immune microenvironment.
Lab(s)
Center for Childhood Cancer
Center for Childhood Cancer
Cripe TP. Cancer gene therapy bears fruit. Mol Ther. 2023 Jan 11; Abdelbaki MS, DeWire Schottmiller MD, Cripe TP, Curry RC, Cruze CA, Her L, Demko S, Casey D, Setty B. An open-label multi-center phase 1 safety study of BXQ-350 in children and young adults with relapsed solid tumors, including recurrent malignant brain tumors. Heliyon. 2022 Dec; 8: e12450. Kalathoor S, Rajendran S, Canella A, Raval R, Cripe TP, Mardis ER, Rajappa P. Myeloid cell heterogeneity in the tumor microenvironment and therapeutic implications for childhood central nervous system (CNS) tumors. J Neuroimmunol. 2022 Dec 5; 374: 578009. Cripe TP, Hutzen B, Currier MA, Chen CY, Glaspell AM, Sullivan GC, Hurley JM, Deighen MR, Venkataramany AS, Mo X, Stanek JR, Miller AR, Wijeratne S, Magrini V, Mardis ER, Mendell JR, Chandler DS, Wang PY. Leveraging gene therapy to achieve long-term continuous or controllable expression of biotherapeutics. Sci Adv. 2022 Jul 15; 8: eabm1890. Birnkrant DJ, Bello L, Butterfield RJ, Carter JC, Cripe LH, Cripe TP, McKim DA, Nandi D, Pegoraro E. Cardiorespiratory management of Duchenne muscular dystrophy: emerging therapies, neuromuscular genetics, and new clinical challenges. Lancet Respir Med. 2022 Apr; 10: 403-420. Baliga S, Matsui J, Klamer B, Cetnar A, Ewing A, Cadieux C, Gupta A, Setty BA, Roberts RD, Olshefski RS, Cripe TP, Scharschmidt TJ, Aldrink J, Mardis E, Yeager ND, Palmer JD. Clinical outcomes and efficacy of stereotactic body radiation therapy in children, adolescents, and young adults with metastatic solid tumors. Br J Radiol. 2022 Feb 10; 20211088. Gupta A, Cripe TP. Immunotherapies for Pediatric Solid Tumors: A Targeted Update. Paediatr Drugs. 2022 Jan; 24: 1-12. Aggarwal P, Luo W, Pehlivan KC, Hoang H, Rajappa P, Cripe TP, Cassady KA, Lee DA, Cairo MS. Pediatric versus adult high grade glioma: Immunotherapeutic and genomic considerations. Front Immunol. 2022; 13: 1038096. Wedekind MF, Miller KE, Chen CY, Wang PY, Hutzen BJ, Currier MA, Nartker B, Roberts RD, Boon L, Conner J, LaHaye S, Kelly BJ, Gordon D, White P, Mardis ER, Cripe TP. Endogenous retrovirus envelope as a tumor-associated immunotherapeutic target in murine osteosarcoma. iScience. 2021 Jul 23; 24: 102759. McKim DA, Cripe TP, Cripe LH. The effect of emerging molecular and genetic therapies on cardiopulmonary disease in Duchenne muscular dystrophy. Pediatr Pulmonol. 2021 Apr; 56: 729-737. Lipschitz N, Earl BR, Cripe TP, Samy RN. Oncolytic virotherapy: a potential therapeutic approach for cholesteatoma. Curr Opin Otolaryngol Head Neck Surg. 2020 Oct; 28: 281-285. Wang Y, Stear JH, Swain A, Xu X, Bryce NS, Carnell M, Alieva IB, Dugina VB, Cripe TP, Stehn J, Hardeman EC, Gunning PW. Drug Targeting the Actin Cytoskeleton Potentiates the Cytotoxicity of Low Dose Vincristine by Abrogating Actin-Mediated Repair of Spindle Defects. Mol Cancer Res. 2020 Jul; 18: 1074-1087. Auletta JJ, Adamson PC, Agin JE, Kearns P, Kennedy S, Kieran MW, Ludwinski DM, Knox LJ, McKay K, Rhiner P, Thiele CJ, Cripe TP. Pediatric cancer research: Surviving COVID-19. Pediatr Blood Cancer. 2020 Jun 18; e28435. Charan M, Dravid P, Cam M, Audino A, Gross AC, Arnold MA, Roberts RD, Cripe TP, Pertsemlidis A, Houghton PJ, Cam H. GD2-directed CAR-T cells in combination with HGF-targeted neutralizing antibody (AMG102) prevent primary tumor growth and metastasis in Ewing sarcoma. Int J Cancer. 2020 Jun 1; 146: 3184-3195. Wedekind MF, Cripe TP. Oncolytic Viruses and Their Potential as a Therapeutic Opportunity in Osteosarcoma. Adv Exp Med Biol. 2020; 1258: 77-89. Yonkof JR, Gupta A, Rueda CM, Mangray S, Prince BT, Rangarajan HG, Alshahrani M, Varga E, Cripe TP, Abraham RS. A Novel Pathogenic Variant in CARMIL2 (RLTPR) Causing CARMIL2 Deficiency and EBV-Associated Smooth Muscle Tumors. Front Immunol. 2020; 11: 884. Sette P, Amankulor N, Li A, Marzulli M, Leronni D, Zhang M, Goins WF, Kaur B, Bolyard C, Cripe TP, Yu J, Chiocca EA, Glorioso JC, Grandi P. GBM-Targeted oHSV Armed with Matrix Metalloproteinase 9 Enhances Anti-tumor Activity and Animal Survival. Mol Ther Oncolytics. 2019 Dec 20; 15: 214-222. Hutzen B, Paudel SN, Naeimi Kararoudi M, Cassady KA, Lee DA, Cripe TP. Immunotherapies for pediatric cancer: current landscape and future perspectives. Cancer Metastasis Rev. 2019 Dec; 38: 573-594. Hutzen B, Ghonime M, Lee J, Mardis ER, Wang R, Lee DA, Cairo MS, Roberts RD, Cripe TP, Cassady KA. Immunotherapeutic Challenges for Pediatric Cancers. Mol Ther Oncolytics. 2019 Dec 20; 15: 38-48. Streby KA, Currier MA, Triplet M, Ott K, Dishman DJ, Vaughan MR, Ranalli MA, Setty B, Skeens MA, Whiteside S, Yeager ND, Haworth KB, Simpson K, Conner J, Cripe TP. First-in-Human Intravenous Seprehvir in Young Cancer Patients: A Phase 1 Clinical Trial. Mol Ther. 2019 Nov 6; 27: 1930-1938. Samy RN, Earl BR, Lipschitz N, Schweinzger I, Currier M, Cripe T. Engineered oncolytic virus for the treatment of cholesteatoma: A pilot in vivo study. Laryngoscope Investig Otolaryngol. 2019 Oct; 4: 532-542. Davis KA, Dodeja AK, Clark A, Hor K, Baker P, Cripe LH, Cripe TP. Use of Cardiac MRI to Assess Antitumor Efficacy of Everolimus in Sporadic Cardiac Rhabdomyoma. Pediatrics. 2019 Jun; 143: Samy RN, Lipschitz N, Earl BR, Cripe TP. Evidence for Oncolytic Viral Eradication of Cholesteatoma In Vitro. Otolaryngol Head Neck Surg. 2019 May; 160: 891-893. Orienti I, Cripe TP, Currier MA, Cavallari C, Teti G, Falconi M. A Cationic Nanomicellar Complex of the Quaternary Amphiphilic Amine RC16+ with Fenretinide as a New Multitasking System for Antitumor Therapy. Curr Drug Deliv. 2019; 16: 807-817. Wedekind MF, Denton NL, Chen CY, Cripe TP. Pediatric Cancer Immunotherapy: Opportunities and Challenges. Paediatr Drugs. 2018 Oct; 20: 395-408. Wedekind MF, Wagner LM, Cripe TP. Immunotherapy for osteosarcoma: Where do we go from here? Pediatr Blood Cancer. 2018 Sep; 65: e27227. Sprague L, Braidwood L, Conner J, Cassady KA, Benencia F, Cripe TP. Please stand by: how oncolytic viruses impact bystander cells. Future Virol. 2018 Sep; 13: 671-680. Cripe TP. After Hollywood Opened the Door, What Do We See in the Halls of Academic Medicine? Acad Med. 2018 Aug; 93: 1099-1100. Fu X, Tao L, Wang PY, Cripe TP, Zhang X. Comparison of infectivity and spread between HSV-1 and HSV-2 based oncolytic viruses on tumor cells with different receptor expression profiles. Oncotarget. 2018 Apr 20; 9: 21348-21358. Sprague L, Lee JM, Hutzen BJ, Wang PY, Chen CY, Conner J, Braidwood L, Cassady KA, Cripe TP. High Mobility Group Box 1 Influences HSV1716 Spread and Acts as an Adjuvant to Chemotherapy. Viruses. 2018 Mar 15; 10: Chen CY, Hutzen B, Wedekind MF, Cripe TP. Oncolytic virus and PD-1/PD-L1 blockade combination therapy. Oncolytic Virother. 2018; 7: 65-77. Franson T, Kinnett K, Cripe TP. Unique Burdens of Pediatric Clinical Trials in Duchenne Muscular Dystrophy, April 20-21, 2017, Bethesda, Maryland, USA. Ther Innov Regul Sci. 2018 Jan 1; 2168479018764650.
View More Publications
- Cripe TP. Cancer gene therapy bears fruit. Mol Ther. 2023 Jan 11;
- Abdelbaki MS, DeWire Schottmiller MD, Cripe TP, Curry RC, Cruze CA, Her L, Demko S, Casey D, Setty B. An open-label multi-center phase 1 safety study of BXQ-350 in children and young adults with relapsed solid tumors, including recurrent malignant brain tumors. Heliyon. 2022 Dec; 8: e12450.
- Kalathoor S, Rajendran S, Canella A, Raval R, Cripe TP, Mardis ER, Rajappa P. Myeloid cell heterogeneity in the tumor microenvironment and therapeutic implications for childhood central nervous system (CNS) tumors. J Neuroimmunol. 2022 Dec 5; 374: 578009.
- Cripe TP, Hutzen B, Currier MA, Chen CY, Glaspell AM, Sullivan GC, Hurley JM, Deighen MR, Venkataramany AS, Mo X, Stanek JR, Miller AR, Wijeratne S, Magrini V, Mardis ER, Mendell JR, Chandler DS, Wang PY. Leveraging gene therapy to achieve long-term continuous or controllable expression of biotherapeutics. Sci Adv. 2022 Jul 15; 8: eabm1890.
- Birnkrant DJ, Bello L, Butterfield RJ, Carter JC, Cripe LH, Cripe TP, McKim DA, Nandi D, Pegoraro E. Cardiorespiratory management of Duchenne muscular dystrophy: emerging therapies, neuromuscular genetics, and new clinical challenges. Lancet Respir Med. 2022 Apr; 10: 403-420.
- Baliga S, Matsui J, Klamer B, Cetnar A, Ewing A, Cadieux C, Gupta A, Setty BA, Roberts RD, Olshefski RS, Cripe TP, Scharschmidt TJ, Aldrink J, Mardis E, Yeager ND, Palmer JD. Clinical outcomes and efficacy of stereotactic body radiation therapy in children, adolescents, and young adults with metastatic solid tumors. Br J Radiol. 2022 Feb 10; 20211088.
- Gupta A, Cripe TP. Immunotherapies for Pediatric Solid Tumors: A Targeted Update. Paediatr Drugs. 2022 Jan; 24: 1-12.
- Aggarwal P, Luo W, Pehlivan KC, Hoang H, Rajappa P, Cripe TP, Cassady KA, Lee DA, Cairo MS. Pediatric versus adult high grade glioma: Immunotherapeutic and genomic considerations. Front Immunol. 2022; 13: 1038096.
- Wedekind MF, Miller KE, Chen CY, Wang PY, Hutzen BJ, Currier MA, Nartker B, Roberts RD, Boon L, Conner J, LaHaye S, Kelly BJ, Gordon D, White P, Mardis ER, Cripe TP. Endogenous retrovirus envelope as a tumor-associated immunotherapeutic target in murine osteosarcoma. iScience. 2021 Jul 23; 24: 102759.
- McKim DA, Cripe TP, Cripe LH. The effect of emerging molecular and genetic therapies on cardiopulmonary disease in Duchenne muscular dystrophy. Pediatr Pulmonol. 2021 Apr; 56: 729-737.
- Lipschitz N, Earl BR, Cripe TP, Samy RN. Oncolytic virotherapy: a potential therapeutic approach for cholesteatoma. Curr Opin Otolaryngol Head Neck Surg. 2020 Oct; 28: 281-285.
- Wang Y, Stear JH, Swain A, Xu X, Bryce NS, Carnell M, Alieva IB, Dugina VB, Cripe TP, Stehn J, Hardeman EC, Gunning PW. Drug Targeting the Actin Cytoskeleton Potentiates the Cytotoxicity of Low Dose Vincristine by Abrogating Actin-Mediated Repair of Spindle Defects. Mol Cancer Res. 2020 Jul; 18: 1074-1087.
- Auletta JJ, Adamson PC, Agin JE, Kearns P, Kennedy S, Kieran MW, Ludwinski DM, Knox LJ, McKay K, Rhiner P, Thiele CJ, Cripe TP. Pediatric cancer research: Surviving COVID-19. Pediatr Blood Cancer. 2020 Jun 18; e28435.
- Charan M, Dravid P, Cam M, Audino A, Gross AC, Arnold MA, Roberts RD, Cripe TP, Pertsemlidis A, Houghton PJ, Cam H. GD2-directed CAR-T cells in combination with HGF-targeted neutralizing antibody (AMG102) prevent primary tumor growth and metastasis in Ewing sarcoma. Int J Cancer. 2020 Jun 1; 146: 3184-3195.
- Wedekind MF, Cripe TP. Oncolytic Viruses and Their Potential as a Therapeutic Opportunity in Osteosarcoma. Adv Exp Med Biol. 2020; 1258: 77-89.
- Yonkof JR, Gupta A, Rueda CM, Mangray S, Prince BT, Rangarajan HG, Alshahrani M, Varga E, Cripe TP, Abraham RS. A Novel Pathogenic Variant in CARMIL2 (RLTPR) Causing CARMIL2 Deficiency and EBV-Associated Smooth Muscle Tumors. Front Immunol. 2020; 11: 884.
- Sette P, Amankulor N, Li A, Marzulli M, Leronni D, Zhang M, Goins WF, Kaur B, Bolyard C, Cripe TP, Yu J, Chiocca EA, Glorioso JC, Grandi P. GBM-Targeted oHSV Armed with Matrix Metalloproteinase 9 Enhances Anti-tumor Activity and Animal Survival. Mol Ther Oncolytics. 2019 Dec 20; 15: 214-222.
- Hutzen B, Paudel SN, Naeimi Kararoudi M, Cassady KA, Lee DA, Cripe TP. Immunotherapies for pediatric cancer: current landscape and future perspectives. Cancer Metastasis Rev. 2019 Dec; 38: 573-594.
- Hutzen B, Ghonime M, Lee J, Mardis ER, Wang R, Lee DA, Cairo MS, Roberts RD, Cripe TP, Cassady KA. Immunotherapeutic Challenges for Pediatric Cancers. Mol Ther Oncolytics. 2019 Dec 20; 15: 38-48.
- Streby KA, Currier MA, Triplet M, Ott K, Dishman DJ, Vaughan MR, Ranalli MA, Setty B, Skeens MA, Whiteside S, Yeager ND, Haworth KB, Simpson K, Conner J, Cripe TP. First-in-Human Intravenous Seprehvir in Young Cancer Patients: A Phase 1 Clinical Trial. Mol Ther. 2019 Nov 6; 27: 1930-1938.
- Samy RN, Earl BR, Lipschitz N, Schweinzger I, Currier M, Cripe T. Engineered oncolytic virus for the treatment of cholesteatoma: A pilot in vivo study. Laryngoscope Investig Otolaryngol. 2019 Oct; 4: 532-542.
- Davis KA, Dodeja AK, Clark A, Hor K, Baker P, Cripe LH, Cripe TP. Use of Cardiac MRI to Assess Antitumor Efficacy of Everolimus in Sporadic Cardiac Rhabdomyoma. Pediatrics. 2019 Jun; 143:
- Samy RN, Lipschitz N, Earl BR, Cripe TP. Evidence for Oncolytic Viral Eradication of Cholesteatoma In Vitro. Otolaryngol Head Neck Surg. 2019 May; 160: 891-893.
- Orienti I, Cripe TP, Currier MA, Cavallari C, Teti G, Falconi M. A Cationic Nanomicellar Complex of the Quaternary Amphiphilic Amine RC16+ with Fenretinide as a New Multitasking System for Antitumor Therapy. Curr Drug Deliv. 2019; 16: 807-817.
- Wedekind MF, Denton NL, Chen CY, Cripe TP. Pediatric Cancer Immunotherapy: Opportunities and Challenges. Paediatr Drugs. 2018 Oct; 20: 395-408.
- Wedekind MF, Wagner LM, Cripe TP. Immunotherapy for osteosarcoma: Where do we go from here? Pediatr Blood Cancer. 2018 Sep; 65: e27227.
- Sprague L, Braidwood L, Conner J, Cassady KA, Benencia F, Cripe TP. Please stand by: how oncolytic viruses impact bystander cells. Future Virol. 2018 Sep; 13: 671-680.
- Cripe TP. After Hollywood Opened the Door, What Do We See in the Halls of Academic Medicine? Acad Med. 2018 Aug; 93: 1099-1100.
- Fu X, Tao L, Wang PY, Cripe TP, Zhang X. Comparison of infectivity and spread between HSV-1 and HSV-2 based oncolytic viruses on tumor cells with different receptor expression profiles. Oncotarget. 2018 Apr 20; 9: 21348-21358.
- Sprague L, Lee JM, Hutzen BJ, Wang PY, Chen CY, Conner J, Braidwood L, Cassady KA, Cripe TP. High Mobility Group Box 1 Influences HSV1716 Spread and Acts as an Adjuvant to Chemotherapy. Viruses. 2018 Mar 15; 10:
- Chen CY, Hutzen B, Wedekind MF, Cripe TP. Oncolytic virus and PD-1/PD-L1 blockade combination therapy. Oncolytic Virother. 2018; 7: 65-77.
- Franson T, Kinnett K, Cripe TP. Unique Burdens of Pediatric Clinical Trials in Duchenne Muscular Dystrophy, April 20-21, 2017, Bethesda, Maryland, USA. Ther Innov Regul Sci. 2018 Jan 1; 2168479018764650.
Education
Date of Appointment at Nationwide Children’s Hospital: 01/27/2012
Board Certifications
Pediatric Hematology Oncology
Fellowship
The Children’s Hospital - University of Colorado
Date Completed: 06/30/1995
Fellowship
Boston Children’s Hospital
Date Completed: 06/30/1993
Residency
University of Iowa Hospitals and Clinics
Date Completed: 07/01/1992
Medical School
University of Iowa
Date Completed: 05/06/1989
Education
Date of Appointment at Nationwide Children’s Hospital: 01/27/2012
Board Certifications
Pediatric Hematology Oncology
Fellowship
The Children’s Hospital - University of Colorado
Date Completed: 06/30/1995
Fellowship
Boston Children’s Hospital
Date Completed: 06/30/1993
Residency
University of Iowa Hospitals and Clinics
Date Completed: 07/01/1992
Medical School
University of Iowa
Date Completed: 05/06/1989
Education
Date of Appointment at Nationwide Children’s Hospital: 01/27/2012
Board Certifications
Pediatric Hematology Oncology
Fellowship
The Children’s Hospital - University of Colorado
Date Completed: 06/30/1995
Fellowship
Boston Children’s Hospital
Date Completed: 06/30/1993
Residency
University of Iowa Hospitals and Clinics
Date Completed: 07/01/1992
Medical School
University of Iowa
Date Completed: 05/06/1989
Date of Appointment at Nationwide Children’s Hospital: 01/27/2012
Board Certifications
Pediatric Hematology Oncology
Fellowship
The Children’s Hospital - University of Colorado
Date Completed: 06/30/1995
Fellowship
Boston Children’s Hospital
Date Completed: 06/30/1993
Residency
University of Iowa Hospitals and Clinics
Date Completed: 07/01/1992
Medical School
University of Iowa
Date Completed: 05/06/1989
Date of Appointment at Nationwide Children’s Hospital: 01/27/2012
Board Certifications
Pediatric Hematology Oncology
Fellowship
The Children’s Hospital - University of Colorado
Date Completed: 06/30/1995
Fellowship
Boston Children’s Hospital
Date Completed: 06/30/1993
Residency
University of Iowa Hospitals and Clinics
Date Completed: 07/01/1992
Medical School
University of Iowa
Date Completed: 05/06/1989
- Pediatric Hematology Oncology
Contact Information
Pediatrics
Call us at: (614) 722-3550
Fax us at: (614) 722-3369
Hematology & Oncology700 Children's DrColumbus, OH 43205 (map)
Contact Information
Pediatrics
Call us at: (614) 722-3550
Fax us at: (614) 722-3369
Hematology & Oncology700 Children's DrColumbus, OH 43205 (map)
Contact Information
Pediatrics
Call us at: (614) 722-3550
Fax us at: (614) 722-3369
Hematology & Oncology700 Children's DrColumbus, OH 43205 (map)
Pediatrics
Call us at: (614) 722-3550
Fax us at: (614) 722-3369
Hematology & Oncology700 Children's DrColumbus, OH 43205 (map)
Call us at: (614) 722-3550
Fax us at: (614) 722-3369
Hematology & Oncology700 Children's DrColumbus, OH 43205 (map)
Call us at: (614) 722-3550
Fax us at: (614) 722-3369
Hematology & Oncology700 Children's DrColumbus, OH 43205 (map)
- Call us at:
- (614) 722-3550
- Fax us at:
- (614) 722-3369
- Hematology & Oncology700 Children’s DrColumbus, OH 43205 (map)
